These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 26662296)

  • 21. The Prevalence of Overactive Bladder Symptoms in Women in Algeria, Egypt, Jordan and Lebanon: A Cross-Sectional Population-Based Survey.
    Al Edwan G; Abdelazim MS; Salhab SE; Jamal YM; Soliman MA
    Adv Ther; 2021 Feb; 38(2):1155-1167. PubMed ID: 33354738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies.
    Kelleher CJ; Dmochowski RR; Berriman S; Kopp ZS; Carlsson M
    BJU Int; 2012 Aug; 110(3):392-400. PubMed ID: 22129365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of symptom bother and health-related quality of life in Japanese female patients with overactive bladder.
    Gotoh M; Kobayashi T; Sogabe K
    Neurourol Urodyn; 2015 Nov; 34(8):730-5. PubMed ID: 25212503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of a 3-item OAB awareness tool.
    Coyne KS; Margolis MK; Bavendam T; Roberts R; Elinoff V
    Int J Clin Pract; 2011 Feb; 65(2):219-24. PubMed ID: 21235701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.
    Anger JT; Goldman HB; Luo X; Carlsson MO; Chapman D; Zou KH; Russell D; Ntanios F; Esinduy CB; Clemens JQ
    Neurourol Urodyn; 2018 Jan; 37(1):213-222. PubMed ID: 28455944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder.
    Bolge SC; McDonnell DD; Chen A; Wan GJ
    Curr Med Res Opin; 2007 Aug; 23(8):1903-12. PubMed ID: 17610806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Understanding the elements of overactive bladder: questions raised by the EPIC study.
    Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
    BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Burden of illness associated with lower urinary tract symptoms including overactive bladder/urinary incontinence.
    Kannan H; Radican L; Turpin RS; Bolge SC
    Urology; 2009 Jul; 74(1):34-8. PubMed ID: 19428076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is there a difference between women with or without detrusor overactivity complaining of symptoms of overactive bladder?
    Giarenis I; Mastoroudes H; Srikrishna S; Robinson D; Cardozo L
    BJU Int; 2013 Aug; 112(4):501-7. PubMed ID: 23452071
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China.
    Wang Y; Xu K; Hu H; Zhang X; Wang X; Na Y; Kang X
    Neurourol Urodyn; 2011 Nov; 30(8):1448-55. PubMed ID: 21826714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of stress urinary incontinence and overactive bladder on micturition patterns and health-related quality of life.
    Oh SJ; Ku JH
    Int Urogynecol J Pelvic Floor Dysfunct; 2007 Jan; 18(1):65-71. PubMed ID: 16575487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of overactive bladder on work productivity.
    Coyne KS; Sexton CC; Thompson CL; Clemens JQ; Chen CI; Bavendam T; Dmochowski R
    Urology; 2012 Jul; 80(1):97-103. PubMed ID: 22748868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bladder symptoms assessed with overactive bladder questionnaire in Parkinson's disease.
    Iacovelli E; Gilio F; Meco G; Fattapposta F; Vanacore N; Brusa L; Giacomelli E; Gabriele M; Rubino A; Locuratolo N; Iani C; Pichiorri F; Colosimo C; Carbone A; Palleschi G; Inghilleri M
    Mov Disord; 2010 Jul; 25(9):1203-9. PubMed ID: 20310046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
    Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
    BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Socioeconomic status and health-related quality of life among adults and older with overactive bladder.
    Kosilov K; Loparev S; Kuzina I; Kosilova L; Prokofyeva A
    Int J Qual Health Care; 2019 May; 31(4):289-297. PubMed ID: 30107414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Psychometric validation of the OAB-V8 and OAB-V3 scales for the screening of patients with probable overactive bladder in the Spanish population].
    Brenes FJ; Angulo JC; Ochayta D; Rejas J; Arumí D; Cañadas A; Lizarraga I
    Med Clin (Barc); 2014 Dec; 143(12):521-9. PubMed ID: 24725856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.